Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration

scientific article published on 11 January 2016

Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/BJOPHTHALMOL-2015-307299
P698PubMed publication ID26755642

P50authorChristian PrünteQ55392643
Katja HatzQ99597154
P433issue10
P921main subjectmacular degenerationQ27429789
P304page(s)1341-1345
P577publication date2016-01-11
P1433published inBritish Journal of OphthalmologyQ13443571
P1476titleChanging from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration
P478volume100

Reverse relations

cites work (P2860)
Q3361273624-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting
Q37699709A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
Q57024766A simulation tool for better management of retinal services
Q90723410Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
Q33840787Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases
Q90100937Increase in the Population of Patients with Neovascular Age-Related Macular Degeneration Who Underwent Long-Term Active Treatment
Q58754638Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
Q64967370Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment.
Q58775553Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect
Q33740174Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA

Search more.